McKesson CorporationMCKEarnings & Financial Report
McKesson Corporation is an American publicly traded company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. The company delivers a third of all pharmaceutical products used or consumed in North America and employs over 80,000 employees. With $308.9 billion in 2024 revenue, it is the ninth-largest company by revenue in the United States and the nation's largest health care company.
MCK Q4 FY2026 Key Financial Metrics
Revenue
$96.3B
Gross Profit
$4.0B
Operating Profit
$2.1B
Net Profit
$1.7B
Gross Margin
4.2%
Operating Margin
2.2%
Net Margin
1.7%
YoY Growth
6.0%
EPS
$13.71
McKesson Corporation Q4 FY2026 Financial Summary
McKesson Corporation reported revenue of $96.3B (up 6.0% YoY) for Q4 FY2026, with a net profit of $1.7B (up 33.5% YoY) (1.7% margin). Cost of goods sold was $92.3B, operating expenses totaled $1.9B.
Key Financial Metrics
| Total Revenue | $96.3B |
|---|---|
| Net Profit | $1.7B |
| Gross Margin | 4.2% |
| Operating Margin | 2.2% |
| Report Period | Q4 FY2026 |
Revenue Breakdown
McKesson Corporation Q4 FY2026 revenue of $96.3B breaks down across 4 segments, led by North American Pharmaceutical at $79.1B (82.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| North American Pharmaceutical | $79.1B | 82.2% |
| Oncology & Multispecialty | $12.7B | 13.2% |
| Medical-Surgical Solutions | $2.9B | 3.0% |
| Prescription Technology Solutions | $1.5B | 1.6% |
McKesson Corporation Annual Revenue by Year
McKesson Corporation annual revenue history includes year-by-year totals (for example, 2026 revenue was $403.4B).
McKesson Corporation Quarterly Revenue & Net Profit History
McKesson Corporation results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2026 | $96.3B | +6.0% | $1.7B | 1.7% |
| Q3 FY2026 | $106.2B | +11.4% | $1.2B | 1.1% |
| Q2 FY2026 | $103.2B | +10.1% | $1.1B | 1.1% |
| Q1 FY2026 | $97.8B | +23.4% | $784.0M | 0.8% |
| Q4 FY2025 | $90.8B | +18.9% | $1.3B | 1.4% |
| Q3 FY2025 | $95.3B | +17.8% | $879.0M | 0.9% |
| Q2 FY2025 | $93.7B | +21.3% | $241.0M | 0.3% |
| Q1 FY2025 | $79.3B | +6.4% | $915.0M | 1.2% |
Income Statement
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $79.28B | $93.65B | $95.29B | $90.82B | $97.83B | $103.15B | $106.16B | $96.30B |
| YoY Growth | 6.4% | 21.3% | 17.8% | 18.9% | 23.4% | 10.1% | 11.4% | 6.0% |
Balance Sheet
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $71.67B | $72.43B | $71.08B | $75.14B | $81.31B | $84.16B | $84.19B | $82.32B |
| Liabilities | $73.42B | $75.45B | $74.17B | $77.21B | N/A | N/A | N/A | N/A |
| Equity | $-1.75B | $-3.02B | $-3.08B | $-2.07B | $-1.97B | $-1.74B | $-1.30B | N/A |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.38B | $2.10B | $-2.38B | $7.75B | $-918.0M | $2.42B | $1.23B | $6.16B |